Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients

Purpose Cognitive functioning is increasingly investigated for its prognostic value in glioblastoma (GBM) patients, but the association of cognitive status during early adjuvant treatment with survival time is unclear. The aim of this study was to determine whether cognitive performance three months...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuro-oncology 2020-08, Vol.149 (1), p.103-111
Hauptverfasser: Butterbrod, Elke, Synhaeve, Nathalie, Rutten, Geert-Jan, Schwabe, Inga, Gehring, Karin, Sitskoorn, Margriet
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 111
container_issue 1
container_start_page 103
container_title Journal of neuro-oncology
container_volume 149
creator Butterbrod, Elke
Synhaeve, Nathalie
Rutten, Geert-Jan
Schwabe, Inga
Gehring, Karin
Sitskoorn, Margriet
description Purpose Cognitive functioning is increasingly investigated for its prognostic value in glioblastoma (GBM) patients, but the association of cognitive status during early adjuvant treatment with survival time is unclear. The aim of this study was to determine whether cognitive performance three months after surgical resection predicted survival time, while using a clinically intuitive time ratio (TR) statistic. Methods Newly diagnosed patients with GBM undergoing resection between November 2010 and February 2018 completed computerized cognitive assessment 3 months after surgery with the CNS Vital Signs battery (8 measures). The association of cognitive performance (continuous Z scores and dichotomous impairment status; impaired vs. unimpaired) with survival time was assessed with multivariate Accelerated Failure Time (AFT) models that also included clinical prognostic factors and covariates related to cognitive performances. Results 114 patients were included in the analyses (median survival time 16.4 months). Of the clinical factors, postoperative Karnofsky Performance Status (TR 1.51), surgical (TR 2.20) and non-surgical (TR 1.94) salvage treatment, and pre-surgical tumor volume (cm 3 , TR 1.003) were significant independent predictors of survival time. Independently of the base model factors and covariates, impairment on Stroop test I and Stroop test III estimated 23% and 26% reduction of survival time (TR 0.77, TR 0.74) respectively, as compared to unimpaired performance. Conclusion These findings suggest that impaired performances on tests of executive control and processing speed in the early phase of adjuvant treatment can reflect a worse prognostic outlook rather than an early treatment effect, and their assessment might allow for early refinement of current prognostic stratification.
doi_str_mv 10.1007/s11060-020-03577-7
format Article
fullrecord <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000546515900001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2422003935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d17ce3733aec4fc4b12555be8fe19fe702916affa6ef89c08dc516ce79277edb3</originalsourceid><addsrcrecordid>eNqNks2P1CAYxhujcWdX_wEPhsSLialCgdJeTMxEV5NNvGjijVD6MsOmhQp0zP73vuus48fBeOAj8HteeHioqieMvmSUqleZMdrSmjbYuFSqVveqDZOK14orfr_aUNaqWvbiy1l1nvM1pVQozh5WZ7xpBadtu6nWbdwFX_wBiJ8X49MMoZCyTwBkjqHsMzGuQCJ5TTtIN8TjQiA-jLAAdggvCUZvS0wkulvs4A9mIsXPWDKQ3eTjMJlc4mzIYopHSX5UPXBmyvD4bryoPr97-2n7vr76ePlh--aqtkKJUo9MWUAr3IAVzoqBNVLKAToHrHegaNOz1jhnWnBdb2k3WslaC6pvlIJx4BfV62PdZR1mGC2encykl-Rnk250NF7_uRP8Xu_iQSshm64TWOD5XYEUv66Qi559tjBNJkBcs25E01DKey4RffYXeh3XFNAeUly1CHU9Us2RsinmnMCdLsOovk1VH1PVmKr-kapWKHr6u42T5GeMCHRH4BsM0WWLj2zhhGHuUrSSyR5nlG19wRhi2MY1FJS--H8p0vxIZyQCfohfJv9x_-9xKNIu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2437639389</pqid></control><display><type>article</type><title>Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients</title><source>Web of Science - Science Citation Index Expanded - 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>Web of Science - Social Sciences Citation Index – 2020&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>SpringerLink Journals - AutoHoldings</source><creator>Butterbrod, Elke ; Synhaeve, Nathalie ; Rutten, Geert-Jan ; Schwabe, Inga ; Gehring, Karin ; Sitskoorn, Margriet</creator><creatorcontrib>Butterbrod, Elke ; Synhaeve, Nathalie ; Rutten, Geert-Jan ; Schwabe, Inga ; Gehring, Karin ; Sitskoorn, Margriet</creatorcontrib><description>Purpose Cognitive functioning is increasingly investigated for its prognostic value in glioblastoma (GBM) patients, but the association of cognitive status during early adjuvant treatment with survival time is unclear. The aim of this study was to determine whether cognitive performance three months after surgical resection predicted survival time, while using a clinically intuitive time ratio (TR) statistic. Methods Newly diagnosed patients with GBM undergoing resection between November 2010 and February 2018 completed computerized cognitive assessment 3 months after surgery with the CNS Vital Signs battery (8 measures). The association of cognitive performance (continuous Z scores and dichotomous impairment status; impaired vs. unimpaired) with survival time was assessed with multivariate Accelerated Failure Time (AFT) models that also included clinical prognostic factors and covariates related to cognitive performances. Results 114 patients were included in the analyses (median survival time 16.4 months). Of the clinical factors, postoperative Karnofsky Performance Status (TR 1.51), surgical (TR 2.20) and non-surgical (TR 1.94) salvage treatment, and pre-surgical tumor volume (cm 3 , TR 1.003) were significant independent predictors of survival time. Independently of the base model factors and covariates, impairment on Stroop test I and Stroop test III estimated 23% and 26% reduction of survival time (TR 0.77, TR 0.74) respectively, as compared to unimpaired performance. Conclusion These findings suggest that impaired performances on tests of executive control and processing speed in the early phase of adjuvant treatment can reflect a worse prognostic outlook rather than an early treatment effect, and their assessment might allow for early refinement of current prognostic stratification.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-020-03577-7</identifier><identifier>PMID: 32643066</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Brain cancer ; Clinical Neurology ; Clinical Study ; Cognitive ability ; Executive function ; Glioblastoma ; Life Sciences &amp; Biomedicine ; Medical prognosis ; Medicine ; Medicine &amp; Public Health ; Neurology ; Neurosciences &amp; Neurology ; Oncology ; Patients ; Science &amp; Technology ; Surgery ; Survival</subject><ispartof>Journal of neuro-oncology, 2020-08, Vol.149 (1), p.103-111</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>12</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000546515900001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c474t-d17ce3733aec4fc4b12555be8fe19fe702916affa6ef89c08dc516ce79277edb3</citedby><cites>FETCH-LOGICAL-c474t-d17ce3733aec4fc4b12555be8fe19fe702916affa6ef89c08dc516ce79277edb3</cites><orcidid>0000-0002-7181-1455</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-020-03577-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-020-03577-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,315,782,786,887,27931,27932,28255,28256,41495,42564,51326</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32643066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Butterbrod, Elke</creatorcontrib><creatorcontrib>Synhaeve, Nathalie</creatorcontrib><creatorcontrib>Rutten, Geert-Jan</creatorcontrib><creatorcontrib>Schwabe, Inga</creatorcontrib><creatorcontrib>Gehring, Karin</creatorcontrib><creatorcontrib>Sitskoorn, Margriet</creatorcontrib><title>Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J NEURO-ONCOL</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose Cognitive functioning is increasingly investigated for its prognostic value in glioblastoma (GBM) patients, but the association of cognitive status during early adjuvant treatment with survival time is unclear. The aim of this study was to determine whether cognitive performance three months after surgical resection predicted survival time, while using a clinically intuitive time ratio (TR) statistic. Methods Newly diagnosed patients with GBM undergoing resection between November 2010 and February 2018 completed computerized cognitive assessment 3 months after surgery with the CNS Vital Signs battery (8 measures). The association of cognitive performance (continuous Z scores and dichotomous impairment status; impaired vs. unimpaired) with survival time was assessed with multivariate Accelerated Failure Time (AFT) models that also included clinical prognostic factors and covariates related to cognitive performances. Results 114 patients were included in the analyses (median survival time 16.4 months). Of the clinical factors, postoperative Karnofsky Performance Status (TR 1.51), surgical (TR 2.20) and non-surgical (TR 1.94) salvage treatment, and pre-surgical tumor volume (cm 3 , TR 1.003) were significant independent predictors of survival time. Independently of the base model factors and covariates, impairment on Stroop test I and Stroop test III estimated 23% and 26% reduction of survival time (TR 0.77, TR 0.74) respectively, as compared to unimpaired performance. Conclusion These findings suggest that impaired performances on tests of executive control and processing speed in the early phase of adjuvant treatment can reflect a worse prognostic outlook rather than an early treatment effect, and their assessment might allow for early refinement of current prognostic stratification.</description><subject>Brain cancer</subject><subject>Clinical Neurology</subject><subject>Clinical Study</subject><subject>Cognitive ability</subject><subject>Executive function</subject><subject>Glioblastoma</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Neurology</subject><subject>Neurosciences &amp; Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Science &amp; Technology</subject><subject>Surgery</subject><subject>Survival</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>AOWDO</sourceid><sourceid>ARHDP</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNks2P1CAYxhujcWdX_wEPhsSLialCgdJeTMxEV5NNvGjijVD6MsOmhQp0zP73vuus48fBeOAj8HteeHioqieMvmSUqleZMdrSmjbYuFSqVveqDZOK14orfr_aUNaqWvbiy1l1nvM1pVQozh5WZ7xpBadtu6nWbdwFX_wBiJ8X49MMoZCyTwBkjqHsMzGuQCJ5TTtIN8TjQiA-jLAAdggvCUZvS0wkulvs4A9mIsXPWDKQ3eTjMJlc4mzIYopHSX5UPXBmyvD4bryoPr97-2n7vr76ePlh--aqtkKJUo9MWUAr3IAVzoqBNVLKAToHrHegaNOz1jhnWnBdb2k3WslaC6pvlIJx4BfV62PdZR1mGC2encykl-Rnk250NF7_uRP8Xu_iQSshm64TWOD5XYEUv66Qi559tjBNJkBcs25E01DKey4RffYXeh3XFNAeUly1CHU9Us2RsinmnMCdLsOovk1VH1PVmKr-kapWKHr6u42T5GeMCHRH4BsM0WWLj2zhhGHuUrSSyR5nlG19wRhi2MY1FJS--H8p0vxIZyQCfohfJv9x_-9xKNIu</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Butterbrod, Elke</creator><creator>Synhaeve, Nathalie</creator><creator>Rutten, Geert-Jan</creator><creator>Schwabe, Inga</creator><creator>Gehring, Karin</creator><creator>Sitskoorn, Margriet</creator><general>Springer US</general><general>Springer Nature</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>17B</scope><scope>AOWDO</scope><scope>ARHDP</scope><scope>BLEPL</scope><scope>DTL</scope><scope>DVR</scope><scope>EGQ</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7181-1455</orcidid></search><sort><creationdate>20200801</creationdate><title>Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients</title><author>Butterbrod, Elke ; Synhaeve, Nathalie ; Rutten, Geert-Jan ; Schwabe, Inga ; Gehring, Karin ; Sitskoorn, Margriet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d17ce3733aec4fc4b12555be8fe19fe702916affa6ef89c08dc516ce79277edb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Brain cancer</topic><topic>Clinical Neurology</topic><topic>Clinical Study</topic><topic>Cognitive ability</topic><topic>Executive function</topic><topic>Glioblastoma</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Neurology</topic><topic>Neurosciences &amp; Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Science &amp; Technology</topic><topic>Surgery</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Butterbrod, Elke</creatorcontrib><creatorcontrib>Synhaeve, Nathalie</creatorcontrib><creatorcontrib>Rutten, Geert-Jan</creatorcontrib><creatorcontrib>Schwabe, Inga</creatorcontrib><creatorcontrib>Gehring, Karin</creatorcontrib><creatorcontrib>Sitskoorn, Margriet</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Web of Knowledge</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science - Social Sciences Citation Index – 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Social Sciences Citation Index</collection><collection>Web of Science Primary (SCIE, SSCI &amp; AHCI)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Butterbrod, Elke</au><au>Synhaeve, Nathalie</au><au>Rutten, Geert-Jan</au><au>Schwabe, Inga</au><au>Gehring, Karin</au><au>Sitskoorn, Margriet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><stitle>J NEURO-ONCOL</stitle><addtitle>J Neurooncol</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>149</volume><issue>1</issue><spage>103</spage><epage>111</epage><pages>103-111</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Purpose Cognitive functioning is increasingly investigated for its prognostic value in glioblastoma (GBM) patients, but the association of cognitive status during early adjuvant treatment with survival time is unclear. The aim of this study was to determine whether cognitive performance three months after surgical resection predicted survival time, while using a clinically intuitive time ratio (TR) statistic. Methods Newly diagnosed patients with GBM undergoing resection between November 2010 and February 2018 completed computerized cognitive assessment 3 months after surgery with the CNS Vital Signs battery (8 measures). The association of cognitive performance (continuous Z scores and dichotomous impairment status; impaired vs. unimpaired) with survival time was assessed with multivariate Accelerated Failure Time (AFT) models that also included clinical prognostic factors and covariates related to cognitive performances. Results 114 patients were included in the analyses (median survival time 16.4 months). Of the clinical factors, postoperative Karnofsky Performance Status (TR 1.51), surgical (TR 2.20) and non-surgical (TR 1.94) salvage treatment, and pre-surgical tumor volume (cm 3 , TR 1.003) were significant independent predictors of survival time. Independently of the base model factors and covariates, impairment on Stroop test I and Stroop test III estimated 23% and 26% reduction of survival time (TR 0.77, TR 0.74) respectively, as compared to unimpaired performance. Conclusion These findings suggest that impaired performances on tests of executive control and processing speed in the early phase of adjuvant treatment can reflect a worse prognostic outlook rather than an early treatment effect, and their assessment might allow for early refinement of current prognostic stratification.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32643066</pmid><doi>10.1007/s11060-020-03577-7</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7181-1455</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0167-594X
ispartof Journal of neuro-oncology, 2020-08, Vol.149 (1), p.103-111
issn 0167-594X
1573-7373
language eng
recordid cdi_webofscience_primary_000546515900001
source Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Web of Science - Social Sciences Citation Index – 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; SpringerLink Journals - AutoHoldings
subjects Brain cancer
Clinical Neurology
Clinical Study
Cognitive ability
Executive function
Glioblastoma
Life Sciences & Biomedicine
Medical prognosis
Medicine
Medicine & Public Health
Neurology
Neurosciences & Neurology
Oncology
Patients
Science & Technology
Surgery
Survival
title Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T00%3A52%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cognitive%20impairment%20three%20months%20after%20surgery%20is%20an%20independent%20predictor%20of%20survival%20time%20in%20glioblastoma%20patients&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Butterbrod,%20Elke&rft.date=2020-08-01&rft.volume=149&rft.issue=1&rft.spage=103&rft.epage=111&rft.pages=103-111&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-020-03577-7&rft_dat=%3Cproquest_webof%3E2422003935%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2437639389&rft_id=info:pmid/32643066&rfr_iscdi=true